Erasca (ERAS) CMO exercises options, sells 20,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Erasca, Inc. Chief Medical Officer Morris Shannon reported an option exercise and related share sale. On March 4, 2026, he exercised options for 20,000 shares of common stock at $1.70 per share and sold 20,000 shares in open-market transactions at a weighted-average price of $15.038 per share. These transactions were carried out under a previously adopted Rule 10b5-1 trading plan. Following a related derivative entry dated March 4, 2025, he held 515,800 stock options, which vest monthly in 48 installments starting February 1, 2024, contingent on continued service.

Insider Trade Summary

Net Seller: 20,000 shares ($300,760)

Net Sell 3 txns

Insider Morris Shannon

Role Chief Medical Officer

Sold 20,000 shs ($301K)

Type	Security	Shares	Price	Value
Exercise	Common Stock	20,000	$1.70	$34K
Sale	Common Stock	20,000	$15.038	$301K
Exercise	Stock Option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Common Stock — 20,000 shares (Direct); Stock Option (right to buy) — 515,800 shares (Direct)

Footnotes (1)

1. The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morris Shannon

(Last) (First) (Middle)

C/O ERASCA, INC.

3115 MERRYFIELD ROW, SUITE 300

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Erasca, Inc. [ ERAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M(1)		20,000	A	$1.7	20,000	D
Common Stock	03/04/2026		S(1)		20,000	D	$15.038(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.7	03/04/2025		M(1)			20,000	(3)	02/04/2034	Common Stock	20,000	$0	515,800	D

Explanation of Responses:

1. The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024.

2. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

	/s/ Ebun Garner, Attorney-in-fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Erasca (ERAS) Chief Medical Officer Morris Shannon report?

Morris Shannon reported exercising options for 20,000 Erasca shares at $1.70 and selling 20,000 common shares at a weighted-average $15.038 on March 4, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Was the Erasca (ERAS) insider sale by Morris Shannon pre-planned under Rule 10b5-1?

Yes. The filing states the option exercise and related sales were executed under a Rule 10b5-1 trading plan adopted on June 30, 2024, indicating transactions were scheduled in advance rather than being discretionary decisions at the time of sale.

At what prices did Erasca (ERAS) insider Morris Shannon exercise and sell shares?

He exercised stock options for 20,000 shares at $1.70 per share and sold 20,000 common shares at a weighted-average price of $15.038, with individual trades occurring between $15.00 and $15.10 according to the footnote disclosure.

How many Erasca (ERAS) stock options does Morris Shannon hold after these transactions?

After the derivative transaction entry dated March 4, 2025, the Form 4 reports that Morris Shannon holds 515,800 stock options, described as a right to buy Erasca common stock, all shown as directly owned following the reported change.

How do Erasca (ERAS) Chief Medical Officer Morris Shannon’s stock options vest?

The filing explains that one forty-eighth of the option grant vests each month, with vesting starting on February 1, 2024. Vesting continues monthly, provided Morris Shannon maintains continuous service with Erasca on each specified vesting date.

What does the weighted-average sale price disclosure mean in the Erasca (ERAS) Form 4?

The Form 4 notes a weighted-average sale price of $15.038, covering multiple trades between $15.00 and $15.10. The insider undertakes to provide detailed trade-by-trade pricing information to the company, shareholders, or SEC staff upon request.